Autopsy report · NCT02601378
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Cause of deathFunding or business
“The combination part of the study was terminated early due to business reasons”
Life of this trial
- Registered 3 months before it started.
- Ran for about 5 years 11 months before it stopped.
- 107 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Uveal Melanoma
- Interventions
- LXS196; LXS196 and HDM201
- Participants
- 107
- Sites
- 6
- Countries
- Australia, France, Netherlands, Norway, Spain, United States
Trials that died the same way
- Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
“Study was terminated early for strategic reasons. Only Part I of the study was completed.” - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
“The study was terminated due to strategic business reasons.” - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
“The study was terminated early due to company decision.” - Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
“The study was terminated due to a business decision.” - Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
“This study was terminated early due to company decision.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.